MedDataX Logo

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

NCT ID: NCT05193006

Last Updated: 2022-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-28

Study Completion Date

2023-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid type, has been further divided into histological patterns of tubulo-papillary, acinar, adenomatoid, micropapillary, or solid. Its prognosis is improved by the use of a locoregional treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), which increases survival up to 50 months. Histology is one of the most important prognostic variable that, forms the basis for treatment decisions. However, the prognostic of the epithelioid type varies greatly due to its tumor heterogeneity. It is therefore necessary to find prognostic factors of malignant epithelioid peritoneal mesothelioma in order to better define the therapeutic strategy. Among histological factors, solid growth, tumor necrosis, nuclear atypia, and mitotic count were found to be independent prognostic factors in epithelioid malignant pleural mesothelioma. However, in epithelioid malignant peritoneal mesothelioma (EMPM), these factors were studied in small and heterogeneous series in terms of histological growth and definitions used for histological factors. The present large study was conducted to investigate the prognostic impact of several histologic factors in EMPM. Their prognosis impacts were assessed using overall survival (OS) and progression-free survival (PFS) in EMPM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer

NCT03253939

Gastric Cancer Peritoneal Carcinomatosis
COMPLETED

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

NCT01812148

Peritoneal Mesotheliomas
COMPLETED

Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan

NCT01226550

Peritoneal Carcinosis (PC)
COMPLETED PHASE1/PHASE2

Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses

NCT04108936

Peritoneal Carcinomatosis
RECRUITING

French National Registry of Rare Peritoneal Surface Malignancies

NCT02834169

Rare Peritoneal Surface Malignancies Pseudomyxoma Peritonei Peritoneal Mesothelioma +5 more
UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Malignant Mesothelioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

peritoneal malignant mesothelioma of grade 1

peritoneal malignant mesothelioma of grade 1

No intervention

Intervention Type OTHER

No intervention

peritoneal malignant mesothelioma of grade 2

peritoneal malignant mesothelioma of grade 2

No intervention

Intervention Type OTHER

No intervention

peritoneal malignant mesothelioma of grade 3

peritoneal malignant mesothelioma of grade 3

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- peritoneal malignant mesothelioma

Exclusion Criteria

* opposition to reuse personnal data
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Gent

Ghent, , Belgium

Site Status RECRUITING

University Hospital of Lyon

Pierre-Bénite, , France

Site Status RECRUITING

Institut f. Pathologie und Neuropathologie

Tübingen, , Germany

Site Status RECRUITING

Zydus Hospitals

Ahmedabad, , India

Site Status RECRUITING

The Norwegian Radium Hospital

Oslo, , Norway

Site Status RECRUITING

Fundação Champalimaud

Lisbon, , Portugal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium France Germany India Norway Portugal

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anne HOORENS, MD

Role: primary

[email protected]
+32 9 332 36 63

Nazim Benzerdkeb, MD

Role: primary

[email protected]
00 44 78 86 44 69

Wiebke Solass Wiebke Solass, MD

Role: primary

[email protected]
07071 29-82270

Loma Parikh Loma Parikh, MD

Role: primary

[email protected]
: +91 9824015858

Ben Davidson Ben Davidson, MD

Role: primary

[email protected]
47-22782415

Mireia Castillo-Martin Mireia Castillo-Martin, MD

Role: primary

[email protected]
+351) 210480048

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL21_1120

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
NCT01617382 RECRUITING
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
NCT02073500 RECRUITING
Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)
NCT06513065 RECRUITING PHASE3
Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
NCT05508555 UNKNOWN NA
HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
NCT02082886 COMPLETED
Multivisceral Oncological Resections Involving the Pancreas - An International Multicenter Study
NCT07091097 COMPLETED
Mesopancreas Study in Pancreatic Cancer
NCT05895214 NOT_YET_RECRUITING
Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach
NCT02829788 UNKNOWN
Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis
NCT04122885 UNKNOWN
Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
NCT02741167 UNKNOWN
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study
NCT03150628 TERMINATED PHASE2
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
NCT02630654 COMPLETED
The PET- Retroperitoneal Sarcoma Study
NCT04224948 COMPLETED NA
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
NCT05544253 UNKNOWN PHASE2/PHASE3
Results of CRS and Debulking in PMP Patients
NCT01427101 UNKNOWN
Molecular Characterization of Perivascular Epithelioid Cell Tumors
NCT05617105 UNKNOWN
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
NCT03969784 COMPLETED NA
Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer
NCT02784028 COMPLETED NA
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
NCT06753136 RECRUITING NA
Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment
NCT02544711 COMPLETED NA
A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis
NCT02995850 COMPLETED PHASE1/PHASE2
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
NCT02078700 COMPLETED PHASE2
Thrombin Generation and Platelet Activation in CRS/HIPEC
NCT03034850 COMPLETED
Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
NCT07232810 RECRUITING NA
Imaging Guided Cementoplasty for Pelvic Bone Metastasis
NCT06231628 NOT_YET_RECRUITING NA